New hope for aggressive lymphoma: experimental combo tested in early trial
NCT ID NCT05270057
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-phase trial tests a new drug, loncastuximab tesirine, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with previously untreated aggressive B-cell lymphomas. The main goal is to find the safest dose and see how well the combination is tolerated. The study involves 11 adults with specific lymphoma types, including Burkitt lymphoma and high-grade B-cell lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.